Nureca Limited (NURECA)

Healthcare · Healthcare Equipment & Supplies · NSE · Updated 21 July 2026

₹292.19 ↑ 13.45% (1Y)

🎯 Key Takeaways

Nureca Limited is transitioning from a historically loss-making entity to a profitable healthcare platform player, with recent quarters showing sustained revenue growth and improved margins. The company is executing a strategic shift toward integrated healthcare solutions and manufacturing expansion, supported by strong domestic demand and operational efficiencies.
Revenue declined 15.2% QoQ to ₹26 in Q3FY25.
⚠️ Foreign exchange volatility poses a risk as operations scale and imports may increase. Intense competition in India's healthcare market could pressure

Market Cap

₹260

P/E Ratio

-47.3

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About NURECA 📊 Interactive Charts

📖 The Story

Nureca Limited is transitioning from a historically loss-making entity to a profitable healthcare platform player, with recent quarters showing sustained revenue growth and improved margins. The company is executing a strategic shift toward integrated healthcare solutions and manufacturing expansion, supported by strong domestic demand and operational efficiencies. This marks a clear inflection point after years of volatility, positioning it as an emerging mid-tier player in India's healthcare equipment space.

📰 What's Happening

In Q1 FY27, Nureca reported revenue of ₹40.3 crores, up 18% YoY and 14% QoQ, driven by its consumer healthcare platform strategy and improved gross margins. The company achieved its strongest profitability in 16 quarters with PAT of ₹3.1 crores and operating margin expansion to 8.7%. Management highlighted progress in its manufacturing expansion in Punjab and referenced a $5,203 crore market opportunity by 2030 growing at 9.9% CAGR. The Board approved unaudited Q1 FY26-27 results showing ₹423.14 crores revenue and ₹24.32 crores net profit, while also confirming the merger with Nureca Technologies and the appointment of Ms. Smita Goyal as Whole-time Director.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
Revenue	21	21	31	22	17	20	31	26
Operating Profit	-1	-0	5	2	-6	3	1	-3
OPM %	-16.3%	-13.7%	4.4%	-19.0%	-26.1%	-11.6%	-7.6%	-15.2%
Net Profit	-2	-1	3	0	-4	2	-0	-3
EPS	₹-1.53	₹-0.71	₹2.90	₹0.16	₹-4.15	₹1.66	₹-0.48	₹-2.80

After years of inconsistent performance with frequent losses, Nureca has demonstrated a clear turnaround over the past four quarters, shifting from sporadic profitability to sustained operational improvement. The recent jump in revenue to ₹40.3 crores in Q1 FY27, up 18% YoY, aligns with management's narrative of scaling the consumer healthcare platform and expanding manufacturing capacity. Margin improvements from 7.3% to 8.7% operating margin QoQ reflect cost discipline and better product mix, supporting the profitability seen in both standalone and consolidated results.

🔮 Management Outlook & What's Next

Management projects the Indian healthcare equipment market to reach ₹5,203 crores by 2030 at a 9.9% CAGR and plans to scale manufacturing capacity in Punjab to capitalize on this growth. They emphasized that the integrated healthcare platform strategy is delivering profitable growth, with recent results underscoring progress in margins and PAT. The company also highlighted ongoing strategic initiatives including the merger with Nureca Technologies and leadership succession planning, signaling a focus on long-term structural growth.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Healthcare Equipment & Supplies

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Poly Medicure Limited	15,193	46.4	—	—	—
Fischer Medical Ventures Limited	2,261	59.0	—	—	—
Laxmi Dental Limited	1,105	57.2	—	—	—
Tarsons Products Limited	1,101	36.9	—	—	—
Fabtech Technologies Limited	681	—	—	—	—
Nureca Limited	260	-47.3	—	—	—

🔗 Peer Stock Analyses

POLYMED FISCHER LAXMIDENTL TARSONS FABTECH

⚠️ Risk Factors

Foreign exchange volatility poses a risk as operations scale and imports may increase. Intense competition in India's healthcare market could pressure margins despite current improvements. Regulatory changes in medical device norms or healthcare pricing could impact profitability. While the current ratio is healthy, the company's leverage profile and working capital management remain critical as expansion progresses.

📋 Recent Filings

🧠 Analyst's Read

Nureca is executing a credible turnaround with sequential improvements in revenue, margins, and profitability, underpinned by strategic investments in manufacturing and platform integration. Investors should monitor execution of the Punjab expansion, merger integration with Nureca Technologies, and management's ability to sustain growth in a competitive healthcare equipment landscape.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on NURECA

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-21.

📡 Get AI alerts when NURECA files new disclosures

Track NURECA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track NURECA — Free

Free account · 2 AI queries/day